Pro Medicus Shares Surge on AU$330 million Contract with Trinity Health

Highlights:

• Landmark Deal Secured: Pro Medicus Limited (ASX: PME) has signed a AU$330 million, 10-year contract with US-based Trinity Health, marking its largest customer to date.
• Extensive Network Migration: The deal involves migrating Trinity Health's imaging systems, spanning 93 hospitals and 142 urgent care sites, to Pro Medicus' Visage 7 platform.
• Stock Surge: Shares of Pro Medicus rose 9.4% to AU$249.94 at the time of writing, reflecting strong market confidence in the growth potential of the agreement.

Pro Medicus Limited (ASX: PME), a leading healthcare imaging software developer, has seen its shares climb 9.4% to AU$249.94 at the time of writing following the announcement of a AU$330 million, 10-year agreement with Trinity Health, a major US not-for-profit healthcare organization.

A Landmark Deal for Pro Medicus

The contract, secured through Pro Medicus’ subsidiary Visage Imaging, marks the company’s largest deal to date. Under the agreement, Visage Imaging will transition Trinity Health's legacy imaging systems to its advanced Visage 7 platform. Trinity Health's expansive network includes 93 hospitals, 107 continuing care facilities, and 142 urgent care centers across 26 states, making this a significant win for Pro Medicus.

Dr. Sam Hupert, CEO of Pro Medicus, expressed excitement about the partnership, stating, "Trinity Health is our largest customer to date and the first with a national footprint."

Positive Market Response

The market responded enthusiastically to the announcement, reflecting confidence in the growth potential this deal brings to Pro Medicus. With the Trinity Health contract, the company continues to solidify its presence in the US healthcare sector, leveraging its Visage 7 platform's cutting-edge capabilities.

Pro Medicus’ ability to secure such a significant contract underscores its competitive edge in providing state-of-the-art imaging solutions, positioning it well for future opportunities in the global healthcare industry.

Disclaimer for Kapitales Research

The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com